CSL Statutory Accounts for the Full Year Ended 30 June 2021
Filed with ASX · · 119 pages · English
VP Investor Relations P: +61 3 9389 3407 E: mark.dehring@csl.com.au Media: Jimmy Baker Communications, Asia Pacific P: +61 450 909 211 E: jimmy.baker@csl.com.au Lodged with the ASX under Listing Rule 4.3A. Contents (Previous corresponding period: Year Ended 30 June 2020) Reported • Total revenue up 13% to US$10.3 billion • Net profit after tax for the year attributable to members of the parent ent
Earlier from CSL
- Update on CSL Agreement with uniQure
- Statutory Accounts for the Half Year Ended 31 Dec 2020
- Dividend/Distribution - CSL
- Update on UQ-CSL v451 COVID-19 Vaccine
- Chairmans Address to Shareholders
Later from CSL
- Trading Halt
- Swiss tender offer to acquire 100% of vifor pharma ltd
- Investor Presentation CSL Swiss Tender Acquisition of Vifor
- Successful Completion of A$6.3B Institutional Placement
- CSL completes A$750 million Share Purchase Plan
Follow CSL into a list and get an email when it puts out news.
Follow CSL